Skip to main content

Table 2 Characteristics of postmenopausal breast cancer cases according to trajectory group

From: Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer

Postmenopausal breast cancer cases

T1 «Normal- stable»a

T2 «Normal-overweight»a

T3 «Normal- obesity»a

T4 «Overweight- obesity»a

T5 «Obesity- decrease»a

(n = 7223)

Mean ± SD or n (%)

Mean ± SD or n (%)

Mean ± SD or n (%)

Mean ± SD or n (%)

Mean ± SD or n (%)

Cancer characteristics

Number of cases

3166 (43.8)

2987 (41.4)

885 (12.3)

145 (2.0)

40 (0.6)

Age at diagnosis

63.0 ± 0.13

63.3 ± 0.13

63.7 ± 0.23

62.2 ± 0.52

67.0 ± 1.31

ER/PR status

ER+PR+

1805 (57.0)

1820 (60.9)

591 (66.8)

94 (64.8)

19 (47.5)

ER−PR−

376 (11.9)

327 (11.0)

91 (10.3)

16 (11.0)

4 (10.0)

ER+PR−

614 (19.4)

517 (17.3)

145 (16.4)

16 (11.0)

7 (17.5)

ER−PR+

26 (0.8)

18 (0.6)

1 (0.1)

2 (1.4)

1 (2.5)

Missing

345 (10.9)

305 (10.2)

57 (6.4)

17 (11.7)

9 (22.5)

ER/PR/HER2 statusb

Luminal A-like

1479 (46.7)

1496 (50.1)

481 (54.4)

78 (53.8)

15 (37.5)

Luminal B-like

634 (20.0)

557 (18.7)

167 (18.9)

21 (14.5)

8 (20.0)

HER2+

112 (3.5)

104 (3.5)

25 (2.8)

6 (4.1)

1 (2.5)

TNBC

212 (6.7)

184 (6.2)

58 (6.6)

9 (6.2)

3 (7.5)

Missing

729 (23.0)

646 (21.6)

154 (17.4)

31 (21.4)

13 (32.5)

  1. BMI body mass index, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, MHT menopausal hormone therapy, OC oral contraceptives, PR progesterone receptor, SD standard deviation
  2. aNormal weight: 18.5–24.9 kg/m2; overweight: 25–29.9 kg/m2; obesity: ≥ 30 kg/m2
  3. bLuminal A-like: ER+PR + HER2−; luminal B-like: ER+PR− HER2− or ER+PR− HER2+or ER+PR+HER2+; HER2-enriched: ER- PR- HER2+; TNBC: ER- PR- HER2-